Start-up Festival

Davide Bommarito

Director, Global Markets, Early Stage Banking, HSBC Innovation Banking

Davide heads the Life Sciences & Healthcare early-stage vertical at HSBC Innovation Banking in London. He joined HSBC Innovation Banking to expand the bank's healthcare footprint in the UK and to provide commercial banking services to disruptive Biotech, Biopharma and Tech Bio companies at different growth stages (pre-seed, seed & series A). Prior, Davide was a Vice President in the SVB UK Early-Stage Healthcare division. Davide is a former scientist with advanced degrees (Ph.D. in Immunology & M.Sc. in Medical Biotechnology) and experience in both the financial/banking sector and medical research sector including roles at world-leading research institutions such as King's College London (KCL) and the Dana-Farber Cancer Institute (DFCI)/Harvard.

 

---

Danny Bosch

Angel Investor

Danny Bosch, Ph.D., MBA is an Investor-Operator and the Founder of DGB Strategy, where he provides strategic commercial and fundraising advisory to Seed and Series A ventures. Specialising in venture architecture, Danny helps founders translate complex scientific innovation into scalable, bankable commercial reality for institutional investors.

He is deeply embedded in the UK health and venture ecosystem as a Health Executive in Residence at UCL, a venture-backed advisor, and a mentor for several top-tier accelerators. Danny brings deep institutional insight to his advisory work from his ongoing role as Director of Business Development at Maudsley Enterprise (SLaM NHS FT), as well as his past leadership in architecting data-monetisation models for the London Secure Data Environment (SDE). By combining his Ph.D. in Biomedical Sciences with an Executive MBA, Danny bridges the gap between rigorous clinical evidence and private-sector capital strategy.

---

Chris Coe

Senior Partner, Kingsley Gate

Chris is a Senior Partner at Kingsley Gate.

He works to build executive teams and boards that can lead and guide companies as they compete, respond, evolve in a fast- changing world.

Chris spent over 12 years in Medical publishing, the Pharmaceutical Industry with GD Searle and the MedTech industry in Senior management with Medtronic and Boston Scientific and a venture backed medical imaging company. He then joined joined Korn/Ferry in Executive search.

Chris moved to lead CT Partners in Europe and then the Global Life Sciences practice as Managing Partner, advising small and large MedTech, Biotech and BioPharma in their successful quest for top talent and growth.

In addition, he has played a pivotal part in consulting with his clients on financing and other matters.

---

Filippo Dal Ben

Investment Manager, Pioneer Group

Filippo is Investment Manager at The Pioneer Group, the largest investor and operator of life sciences campuses across the UK and Ireland. In this role, he leads the sourcing and due diligence of innovative companies in drug discovery, medical devices, diagnostics, digital health, and therapeutic platforms. To date, he has successfully facilitated over £6.8m in fundraising across MedTech and Advanced Therapies. 

Previously, he was a founding team member at a start-up focused on diagnostics for blood cancers and infectious diseases and served as a strategic consultant to pharmaceutical companies in the mRNA vaccine sector during the COVID-19 pandemic. 

 

---

Inga Deakin

Partner, Molten VC

Inga brings hands-on investment experience in life sciences and digital health, working with ventures spun out of leading UK universities. Her career has also included time in the US, where she gained international industry and healthcare expertise as Chief of Staff at a commercial-stage genetic molecular diagnostics company, and as Entrepreneur in Residence at Duke University. 

Her scientific foundation includes a DPhil and MSc in Neuroscience from the University of Oxford, complemented by a BA from the University of Cambridge. This blend of academic rigor and industry insight fuels her enthusiasm for supporting innovators who are advancing the future of healthcare.

---

Barbara Domayne-Hayman

KQ Labs Chair & Entrepreneur in Residence, The Francis Crick Institute

Barbara has worked on the commercial side of life sciences for over thirty years, first in a large organisation (ICI/Zeneca/AstraZeneca), before transitioning to the entrepreneurial world of biotech. 

Barbara joined the Francis Crick Institute in January 2018 as Entrepreneur-in-residence, where amongst other things, she co-founded, led and now is Chair of the KQ Labs accelerator, which is focused on start-ups from all over the UK who are making use of data/AI applied to life sciences and healthcare. She is also Chief Business Officer of Autifony, where she is responsible for strategic partnering, fundraising and commercial aspects of drug development for CNS disorders. 

Barbara is a member of the investment committees of Cambridge Enterprise Ventures and of LifeArc Ventures and is also a member of Cambridge Angels. Barbara was Chair of Puridify, a UCL spin-out with a breakthrough biotherapeutics purification technology, which was acquired by GE (now Cytiva) in November 2017.  Previously, Barbara was CEO of Stabilitech, and she was Commercial Director at Arrow Therapeutics until the company was acquired by AstraZeneca. Barbara was also Senior Business Development Manager at Celltech. 

Barbara has a BA and D Phil in Chemistry from the University of Oxford, and is a Sloan Fellow from London Business School.

---

Sally Epstein

Entrepreneur in Residence, Cambridge Innovation Capital

Sally is an AI and science strategist.

Before joining CIC, Sally served as Chief Innovation Officer at Cambridge Consultants, where she led the deep tech incubator and guided investments in quantum technologies, human–machine understanding, and photonics. She also served as a subject matter expert at Darktrace.

Sally holds a PhD from King’s College London and a BA in Mathematics from the University of Oxford.

---

Roya Esat-Dabestani

Knowledge Transfer Manager in Precision Medicine, Innovate UK Business Connect

No bio provided

---

Veronica Falco

Business Development Transactions Manager, Catapult Cell and Gene Therapy

Veronica Falco is a Business Development Transactions Manager at Cell and Gene Therapy (CGT) Catapult, a government-funded research and technology organisation focused on accelerating breakthrough research in advanced therapies to commercialisation and scale. Veronica is responsible for identifying and developing strategic partnerships across the cell and gene therapy ecosystem, working with therapy and technology developers,  CDMO/CROs, pharmaceutical companies, and other key stakeholders in the CGT space. Her work focuses on enabling collaboration that accelerate innovation, support sector growth, and ultimately help translate advanced therapies into patient access. She also serves as Business Development Lead for the organisation’s Cell Delivery programme, contributing to strategy development and driving collaborations aimed at overcoming key barriers such as scalability, cost of goods, and speed to clinic.

Prior to this, she was Principal Consultant at Lindville Bio, where she supported early-stage stem cell therapy developers in navigating translational and commercial challenges. Her work included market and competitive analysis, fundraising and investor engagement strategy, Quality by Design (QbD) implementation, and the development of strategic partnerships to support therapy development. She also contributed to building organisational visibility through conference representation and digital content creation.

Earlier in her career, she worked in a cytogenetics laboratory, gaining hands-on experience across both conventional and molecular cytogenetics while liasing with genetic counselors, clinicians, and patient advocates, to remain abreast of industry advancements. She holds a BSc in Biomedical Sciences from Brunel University London and an MSc in Cell and Gene Therapy from Imperial College London.

---

Emma Fox

Business Operations Manager Incubation EMEA, External Scientific Innovation, Johnson & Johnson

Emma leads core business operations for the ESI incubation model across the EMEA region, serving as a point of contact for portfolio companies and innovation partners. She strengthens partnerships with innovators and internal teams, streamlines operational processes, and contributes to advancing the ESI mission across the region.

Prior to joining Johnson & Johnson, Emma led the KQ Labs Accelerator at the Francis Crick Institute in London, a flagship program supporting startups at the intersection of data science and biomedical research. Over six years, she designed and delivered innovation programs for more than 150 early stage health and life science companies, developing expertise in program design, operational leadership, and network building. Her earlier experience includes managing behavioral medicine research at Northwestern University's Feinberg School of Medicine in Chicago and driving healthcare improvement at Diabetes UK.

Emma holds an MSc in Health Psychology from University College London and an MA (Hons) in Psychology and Social Anthropology from the University of St Andrews.

---

Tori Hammond

Senior Research Commercialisation Manager (lead for Health and Life Sciences), University of Bristol

Tori is the lead for health and life science commercialisation, supporting Bristol academics with the exploitation of intellectual property through licensing and the formation of spin-out companies. Tori joined the University of Bristol in June 2024 after a decade working in technology transfer at Imperial College London, University of Exeter and Guy’s and St Thomas’ NHS Trust. Before this, Tori worked in drug discovery R&D at GlaxoSmithKline and holds a PhD in biochemistry and a degree in molecular biology from the University of Bath.

---

Julian Hanak

Entrepreneur in Residence, University of Bristol

Julian has held leadership roles in the biotechnology and gene therapy sector for more than 30 years, working in both small biotech, CDMO and large pharma companies. Most recently he was CEO of Purespring Therapeutics, seeing the company through its $100M+ Series B raise. He has also held senior positions at Nightstar Therapeutics, Cobra Biomanufacturing, Biogen and AstraZeneca.

With special interests in early stage company and product development Julian is currently Entrepreneur in Residence at the University of Bristol.

---

Nataly Hastings

CEO, Cellestial Health

Dr Nat Hastings has background in clinical research and bioengineering at the University of Cambridge, focussing on Parkinson's disease modification and brain cell network communication. She led the relevant academic project since 2018 and managed the Cellestial Health spin-out process in 2023. As the CEO of Cellestial Health, her goal is to transform academic insights into a tangible patient benefit. 

---

Anthony Holmes

Director of Science and Technology, NC3Rs

Dr Anthony Holmes is Director of Science and Technology at the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs; www.nc3rs.org.uk). He has strategic oversight of the science and technology supported through NC3Rs; ensuring that the NC3Rs has a long-term and sustainable strategy for supporting the best science and technology and its use in practice to achieve 3Rs and wider scientific and economic benefits. He leads the CRACK IT open innovation programme. Anthony has a PhD from the University of Cambridge and worked as a post-doctoral researcher at the Babraham Institute, Cambridge exploring the molecular mechanisms behind calcium signalling pathways and their role in human health and disease.

---

Jonathan Kwok

Co-Founder & CEO, Infinitopes

Dr. Kwok is a clinician scientist and Cancer Research UK (CRUK) cancer vaccines fellow at Oxford University. He enjoys more than two decades of professional experience across the fields of oncology, vaccinology, clinical trials, strategy consulting and investment banking. He co-founded Infinitopes Precision Immunomics in 2021, bringing together world leading experts in antigen discovery, T-cell immunology, computation/ML, vaccine design/molecular biology, biomanufacturing and medicines regulation. His mission is to develop accessible, high efficiency vaccines to prevent cancer metastases.

---

Oliver Lyth

Associate, M Ventures

Oliver Lyth, PhD, is an Associate in the M Ventures Biotechnology team having joined in 2024. Oliver holds an MBiochem from the University of Oxford and completed his PhD in Molecular Parasitology at Imperial College where his research centred on how the malaria parasite infects red blood cells. Previously, Oliver acted as an Analyst in the due diligence team supporting LifeArc Ventures before joining IP Group’s Life Sciences Partnership as an Investment Manager where he led deal flow and diligence activities for the review of Biotech investment opportunities with a focus on therapeutics. Oliver is based in London and Amsterdam.

---

Lydia Mapstone

Co-Founder & CEO, BoobyBiome

Lydia is the CEO and Co-founder of BoobyBiome, a company leveraging their expertise in breast milk research to provide solutions for improving infant gut health. As a microbiologist, Lydia is passionate about solving problems in healthcare by using biotechnology. Lydia has pursued this interest throughout her career; winning the Best Therapeutic prize at the international synthetic biology competition iGEM (2017), through her PhD research at University College London where she has published, presented and won multiple awards for her research (2017-2022) and by winning the UCL Grand Challenges award to set up the first UK infant microbiome conference at the Institute of Child Health, Great Ormond Street Hospital (2020).

During her time at BoobyBiome, Lydia was an awardee of Innovate UK’s prestigious Women in Innovation 2023 prize and has led her team to win five other awards from the BBBSRC and Innovate UK. Keen to share her expertise, Lydia became a member of the Women in Innovation Community Forum (2025-2026) to advise the UK government on funding female entrepreneurship and is a frequent guest lecturer on university courses run by Birkbeck University, UCL and Imperial.

---

Abigail Martin

Co-Founder & CCO, ImmuONE

Dr Abigail Martin is a scientist turned entrepreneur in biotech, with a passion for applying research to the commercial world. She cofounded university spin out ImmuONE in 2019 with the aim to engage with inhalation and allergy industries, advocating for standardised in vitro technologies. With early on support from Innovate UK followed by recent seed investment of +£2M, she continues to lead the revenue making venture from start up to scale up. As CEO, she is passionate about supporting alternative methods to animal testing, empowering her colleagues and navigating ImmuONE on its growth trajectory. To date the company has launched multiple human-lung and immune in-vitro products, offering standard testing and advanced assays to assist clients in bringing products to market. 

---

Phil Masterson

Associate Director, Ventures, Cancer Research Horizons

Phil has a BSc in Cell Biology from the University of Essex, and a PhD in Virology from the University of Cambridge. After a post-doc position at the National Institute for Medical Research (NIMR) in London, Phil spent a number of years managing R&D programmes in the biotech industry. 

He moved into technology transfer in 2003 when he joined Cancer Research Horizons (formerly called Cancer Research Technology). Since that time, he has built up extensive experience of managing and commercialising healthcare technologies from academic origins, focusing in recent years on the creation of innovative and transformative oncology ventures, from ideation to launch.  

He has served as a Board Director or Observer for a range of start-up companies including Artios Pharma, Monte Rosa Therapeutics, Infinitopes, MyT BIO, Elaitra and Oncodrug.

---

Chris Molloy

CEO, BIA

Chris Molloy is a senior international life sciences executive, scientist, board director and advisor with more than 35 years’ experience across pharmaceuticals, biotechnology, diagnostics, digital health, data science and healthcare innovation. 

His career has spanned leadership roles from global drug discovery at Glaxo to venture-backed biotech, R&D technology, executive search and national innovation strategy. He founded and led Medicines Discovery Catapult, the UK’s national centre for drug discovery innovation, and during the COVID-19 pandemic served as founding Director of the UK’s Lighthouse Labs network, the largest diagnostic programmes in British history. 

Chris has chaired and advised multiple biotech and healthcare companies, supported governments and investors internationally. He serves as a Trustee of The Institute of Cancer Research, is an Honorary Professor at The University of Manchester, and is Independent Chair of PharosAI. 

---

Jack O'Meara

CEO, Aerska

Jack O’Meara is the CEO of Aerska, a biotech company developing RNAi medicines to address neurodegenerative diseases. Prior to founding Aerska, Jack co-founded and served as CEO of Ochre Bio, which applies advances in data science and organ perfusion to develop RNAi medicines for patients suffering from liver diseases. Between both he has raised over $100M in top tier venture capital and closed pharma partnership deals worth up to $1B. He began his career in management consulting, where he supported the global launch of Zolgensma at Novartis Gene Therapies. Jack holds technical degrees from the University of Galway in Ireland and the University of Notre Dame in the United States. His work has been featured in The Wall Street Journal, Forbes, and the Financial Times.

---

Kerstin Papenfuss

CEO, Big Picture Bio

Dr. Kerstin Papenfuss is a proven leader in therapeutic venture creation, specializing in translating groundbreaking scientific ideas into successful companies. With a PhD in tumour immunology and an Executive MBA, her background perfectly anchors Big Picture Bio's focus on complex immune microenvironments. Her career spans impactful translational roles at LifeArc and the UK's Cell and Gene Therapy Catapult, where she incubated companies like PureSpring. At Deep Science Ventures (DSV), Kerstin built the pharma sector from scratch—founding 12 therapeutics and enabling tech companies, and managing a portfolio of 18, including one exit. She has secured major industry collaborations, board directorships, and actively champions female entrepreneurship in deep tech. 

---

Ed Rainsford

Senior Associate, Appleyard Lees

Edward advises both UK and US biotechnology and medical device companies on protecting valuable inventions.  

His sector expertise spans antibodies, cell and gene therapy, gene editing, stem cells, therapeutics, diagnostics, molecular biology and medical devices.  

For these technologies, Edward’s work includes patent drafting, patent prosecution, European Patent Office (EPO) opposition and appeals, proceedings at the Intellectual Property Enterprise Court (IPEC), freedom to operate reports, and registered designs.  

Edward completed his PhD in virology from Warwick University in 2006 studying rotavirus replication. After leaving Warwick University, he worked as a postdoctoral research associate at the University of Virginia researching the rhabdovirus nucleocapsid protein. Edward returned to the UK in 2009 to study for his master’s in intellectual property law at Queen Mary University of London. Edward entered the patent profession in private practice in 2010. 

---

Rosie Rodriguez

President, Growth, Relation Therapeutics

Rosie Rodriguez is President, Growth at Relation and a senior leader in the UK TechBio sector. With over 22 years of experience across Roche, GSK and biotech, she has shaped R&D strategy, partnerships and organisational growth at scale. She brings deep experience building high-performing interdisciplinary organisations and translating scientific excellence into impact through talent, capital and technology.

At Relation, Rosie has played a central role in scaling the company into a recognised sector leader and helping position UK innovation at the forefront of global TechBio. Her remit spans people and culture, partnerships, infrastructure, communications and external engagement, including the creation of a state of the art integrated wet and dry laboratory space in London’s Knowledge Quarter.

Rosie is deeply engaged in London’s TechBio and innovation ecosystem, spanning industry and policy, including through the BioIndustry Association (BIA), where she mentors through Women in Biotech, contributes to policy discussions and has represented the sector at Parliament Days. She is a key voice in London’s TechBio ecosystem, bringing a system-level perspective grounded in experience scaling innovative companies to cross-sector discussions with industry, investors, academia and government on what would materially increase collaboration, scale-up and long-term investment in London.

---

Lea Sefer

Partnerships Manager, Ellele Health

Lea is Partnerships Manager at Ellele Health, where she leads commercial strategy and strategic partnerships for the Ellele Sampling Device and the Women’s Health Biobank. She is responsible for driving growth, building collaborations, and advancing the commercialisation of Ellele Health’s offering.

Lea brings extensive experience in commercial strategy across the life sciences and healthcare sectors. Prior to joining Ellele Health, she was a consultant at IQVIA and later a Partner at a boutique life sciences consultancy, advising leading pharmaceutical and biotech companies on the commercialisation of therapeutics, vaccines, and companion diagnostics across the EU5 and the United States.

She holds a BSc in Biotechnology from Imperial College London and a PhD in Structural Biology and Drug Discovery from the University of Oxford. Combining deep scientific expertise with strategic and commercial acumen, Lea focuses on translating innovation into real-world impact in women’s health.

---

Fiona Sewell

Head of Toxicology, NC3Rs

Dr Fiona Sewell is a Head of Toxicology at the NC3Rs, where she specialises in animal use in the pharmaceutical and chemical industries.  She convenes expert working groups which take an evidence-based approach to explore and support new opportunities to minimise and refine the use of a variety of species including non-human primates, dogs and rodents.  Her publications include recommendations on the incorporation of recovery animals to support first-in-human clinical trials, an evidence-based approach to define body weight loss limits to refine short-term toxicity studies and evidence to support the use of ‘evident toxicity’ as a refined endpoint in acute inhalation studies.  Fiona joined the NC3Rs in 2012 following a Postdoctoral Research Associate position at Imperial College London.  She has a PhD in translational research from the Cancer Research Clinical Centre at the University of Leeds, and an MSc in Applied Toxicology from the University of Surrey.

---

Oliver Sexton

Investment Director, Future Planet Capital

Oliver is an Investment Director specialising in life science investments he has managed the enlarged £33m engineering biology sub-fund since its inception in 2014. He has invested in a broad range of companies in sectors as diverse as therapeutic, agritech and clean biotech.  

He sits on multiple boards and has overseen exits including the £85m sale of Quethera to Astellas. He is also a member of the Future Planet Capital ESG steering group.  

Previously, Oliver worked at the venture fund Imperial Innovations as well as other roles in the industry. He has a background in strategy analysis and consultancy including roles in New York and has a masters from the University of Bristol and commenced a PhD in bioremediation at the University of Nottingham. 

---

Prashant Shah

Managing Partner, o2h Ventures

o2h Ventures was co-founded by Sunil and Prashant Shah in 2013. In the last 3-4 years, they have co-founded four companies with UK-based academics and entrepreneurs, provided consultancy services to five companies, held Chairman or Director level positions in nine companies, built up a portfolio of twenty early-stage investments, and executed early-stage drug discovery research projects for fifteen different companies. In 2013, bucking a pattern of UK Science going to the USA for funding, Sunil and Prashant acted quickly to lead an academic spin out from the USA with promising data in brain cancer and proceeded to run, externally fund and locate that company, Opal Oncology, in the UK. It provided direct hands-on experience of making the scientific decisions and managing the operations of a therapeutics company.

---

Cole Sims

Business Development Lead, LightOx

Cole Sims is a PhD‑trained, early biotech leader with deep expertise in light-activated therapeutics and translational biology.

Having led asset development as Head of Biology and now as Business Development Lead at LightOx, he bridges scientific development with commercial strategy.

He leads on strategic partnerships across oncology and wound care programmes (both in defence and healthcare).

---

Stasa Stankovic

Co-Founder, Ovartix

Dr Stasa Stankovic is a world leading scientist in reproductive medicine, holding an MPhil and PhD in Reproductive Genomics from the University of Cambridge. She focuses on deciphering genetic architecture of reproductive ageing, fertility and menopause, and their link to other health conditions and longevity in women. Commercialising her PhD, today she is a co-founder and CEO of OvartiX, a women’s health drug discovery company aiming to develop next-generation therapeutics for reproductive disorders like infertility, polycystic ovarian syndrome, menopause etc. She also works as a strategy consultant for AstraZeneca, where she is defining and growing corporate-wide strategy around application of human omics, AI and ML for drug discovery, and Cercle AI, an AI women’s health startup.

Based on her work, she was awarded ‘McKinsey&Company Next Generation Women Leader’ for 2020, the best young investigator under the age of 40 by the International Menopause Society ('Robert Greenblatt Award'), one of ten best UK young scientists in the biomedical sector by the UK Government ‘STEM for Britain’, one of top 100 women in tech in the UK by Barclays, One of top 200 trailblazing women in women’s health and femtech by Covington and Women of Wearables, and she is considered as one of 11 scientists with the highest impact on innovations in menopause and reproductive health by Forbes.

---

Anthony Taylor

UK Commercial Director, Merck

No bio provided

---

Nandy Thaver

Founder & CEO, Thaver

Thaver is led by Nandy Thaver who has over 14 years experience driving revenue growth, leading high-performing teams, and delivering transformative results for global organisations.

Specialising in healthcare, life sciences, and technology, Nandy has a proven record of success in scaling operations, building strategic partnerships, and securing multi-million-dollar contracts across diverse markets.

---

Stuart Thompson

Consultant, SJT Advisory

Stuart is an experienced board-level leadership consultant, and one of the first talent partners recruited into UK venture capital. At IP Group (2006-2024), he personally recruited many of the firm’s deep-science investment professionals, the Group’s plc board non-executives, and key appointments for a broad spectrum of innovative technology companies. These include Chairs for adsilico (In-silico Clinical Trials) and Microbiotica (Microbiome-based therapeutics); and Chief Executives for Oxehealth (Vital signs monitoring), Creavo (Medical Imaging) and Iksuda (ADC Therapeutics). 

Stuart began his career in executive search at Whitehead Mann (1991-2006), gaining a reputation for delivery on assignments, which led to him being chosen by the firm’s Managing Partner (Dr Anna Mann) to support her work, leading the Board Practice. Latterly, he ran the Life Sciences and Healthcare Practice as Partner in charge.

He has an undergraduate degree in Biological Sciences from Birmingham University, and a Certificate in Professional Coaching from Henley Management College (Reading University

---

Jonathan Tobin

Partner, Brandon Capital

Jonathan is a Partner based in Brandon’s London office and serves on the boards of Pheon Therapeutics, Myricx Bio, AstronautX, Salvina, Catalym, and Cincera. Previously, he was a Managing Director at Arix Bioscience, where he built the team and portfolio, sitting on boards including Artios Pharma and VelosBio (acquired by Merck for $2.75bn). Before Arix, Jonathan was a Principal at Touchstone Innovations, helping build biotech spin-outs like Inivata (acquired for $415m). 

Jonathan holds a first-class degree in Biology from Oxford University, a PhD in Molecular Medicine from UCL, and an MBA from Imperial College. He conducted postdoctoral research on cancer cell signalling at Cancer Research UK, publishing in Nature Genetics and NEJM. He is a trustee of the Autism Centre for Excellence, investor-in-residence at Cancer Research Horizons, and part of the KHAN drug discovery fund investment advisory committee. 

---

Tarun Vemulkar

Co-Founder & Chief Technology Officer, Semarion

 Tarun drives the innovation of the SemaCyte® technology platform through novel material design and engineering that is embedded across Semarion’s product suite. 

His background spans running microchip fabrication processes in industry to developing an advanced nanomagnetic therapy for glioblastoma. 

---

Katie Wright

Senior Capital Equipment Specialist

No bio provided

---

Jerry Wu

Managing Director & Head of UK Office, LongRiver

Jerry brings over 27 years of experience in healthcare, venture capital, and cross-border investments. Before joining LongRiver, he led over £250 million in investments as Head of Investment at TusPark Holdings UK, a Cambridge-based VC firm.

His extensive background includes leadership roles at AstraZeneca, where he drove AI and data-driven clinical research, as well as contributions to EMBL-EBI, the Wellcome Trust Sanger Institute, and the Cambridge Institute for Medical Research.

---

Chloe Zhang

Investor Relationships Manager, CPI

Chloe is Investor Relationships Manager of CPI Enterprises, based in London to expand the deep tech investor community, and to engage with academia and SMEs to explore potential investment and partnership opportunities.

Prior to joining CPI, Chloe has 9 years significant experience of the early-stage investment ecosystem. She was partner at China's first and largest Entrepreneurship educational platform and incubator before co-founding a US-China-based micro-VC and accelerator, which she later exited successfully. She then launched the UK entity of a family office and CVC, G5 Capital before joining CPI in 2022. Chloe started her career in media and consulting. She holds an MBA from Imperial College Business School and a MSc in Financial Journalism from City University London.

---